PT Inquest is an online journal club. Hosted by Jason Tuori, Megan Graham, and Chris Juneau, the show looks at an article every week and discusses how it applies to current physical therapy practice.
…
continue reading
Content provided by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Angiogenesis, the Sequel: Does Cyramza (Ramucirumab) Make a Difference for Second Line Treatment?
MP4•Episode home
Manage episode 120493198 series 98519
Content provided by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
301 episodes
MP4•Episode home
Manage episode 120493198 series 98519
Content provided by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by cancerGRACE - H. Jack West, MD, CancerGRACE - H. Jack West, and MD or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The REVEL trial studied 1,200 non-small cell lung cancer patients to see if the drug Cyramza (ramucirumab) improved overall surival. The doctors had mixed feelings about the results.
301 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.